## Clinical Context This patient has supratherapeutic INR (8.2) in the setting of reduced renal clearance. Warfarin is metabolized hepatically, but renal impairment can increase sensitivity through altered protein binding and reduced clearance of metabolites. ## Pharmacokinetic Principle **Key Point:** In asymptomatic patients with INR 5–9 and no bleeding, the standard approach is to withhold warfarin and give low-dose oral vitamin K (2.5 mg), which reverses the effect gradually over 12–24 hours without causing resistance to future anticoagulation. **High-Yield:** Vitamin K 2.5 mg orally is preferred over IV (which risks thrombosis) or higher doses (which cause warfarin resistance for 7–10 days). Renal impairment increases warfarin sensitivity by reducing clearance of active metabolites and altering protein binding dynamics. ## Management Algorithm ```mermaid flowchart TD A[Supratherapeutic INR<br/>Asymptomatic] --> B{INR level?}:::decision B -->|INR 5-9<br/>No bleeding| C[Hold warfarin<br/>Vitamin K 2.5 mg PO]:::action B -->|INR > 9<br/>No bleeding| D[Hold warfarin<br/>Vitamin K 5-10 mg PO]:::action B -->|Any INR<br/>+ Bleeding| E[Fresh frozen plasma<br/>+ Vitamin K 10 mg IV]:::urgent C --> F[Recheck INR in 24-48 hrs]:::action D --> F E --> G[Urgent reversal achieved]:::outcome ``` **Clinical Pearl:** Renal impairment increases warfarin sensitivity; dose reduction is often needed. Monitor INR more frequently in CKD patients. ## Why This Approach 1. Asymptomatic status excludes need for emergent reversal (FFP + vitamin K). 2. Oral vitamin K 2.5 mg is the guideline-recommended dose for INR 5–9 without bleeding. 3. Withholding warfarin prevents further INR rise while vitamin K takes effect. 4. Recheck in 24–48 hours allows assessment of response and safe resumption at a reduced dose.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.